Investigational drug · Phase 2
CHF 6001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Asthma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "CHF 6001"
First trial start
2025
Mar 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CHF 6001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "CHF 6001" as an intervention, largest first.
Chiesi Farmaceutici S.p.A.Industry
NCT01703052 · 74 participants · Start Jul 2011 · Primary completion May 2012
Drug: CHF 6001 SD or placebo; CHF 6001 MD or placebo · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Nottingham, United Kingdom
Chiesi Farmaceutici S.p.A.Industry
NCT03004417 · 61 participants · Start Oct 31, 2016 · Primary completion Dec 28, 2017
Drug: CHF 6001 Dose1; CHF 6001 Dose2 · For: COPD
Sites: Manchester, United Kingdom
Chiesi Farmaceutici S.p.A.Industry
NCT01730404 · 55 participants · Start Oct 2012 · Primary completion Oct 2013
Drug: CHF6001 DPI; Roflumilast and 1 more · For: COPD
Sites: Belfast, Ireland; Harrow, United Kingdom; Manchester, United Kingdom · 5 sites in all
Chiesi Farmaceutici S.p.A.Industry
NCT06900816 · 50 participants · Start Mar 28, 2025 · Primary completion Aug 11, 2025
Drug: CHF 6001; CHF 6001 · For: Asthma
Sites: Sofia, Bulgaria
Chiesi Farmaceutici S.p.A.Industry
NCT02386761 · 48 participants · Start Nov 2014 · Primary completion May 2015
Drug: Single Ascending Dose (SAD); Multiple Ascending Dose (MAD) · For: Chronic Obstructive Pulmonary Disease
Sites: Nottingham, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of M3 Antagonist-PDE4 Inhibitor Dual Pharmacology Molecules for the Treatment of Chronic Obstructive Pulmonary Disease.
Armani E, Rizzi A, Capaldi C, et al. · J Med Chem 2021
- New Avenues for Phosphodiesterase Inhibitors in Asthma.
Matera MG, Ora J, Cavalli F, et al. · J Exp Pharmacol 2021
- The PDE4 inhibitor CHF-6001 and LAMAs inhibit bronchoconstriction-induced remodeling in lung slices.
Kistemaker LEM, Oenema TA, Baarsma HA, et al. · Am J Physiol Lung Cell Mol Physiol 2017
- Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation.
Sulaiman I, Lim JC, Soo HL, et al. · Pulm Pharmacol Ther 2016
- In vitro and in vivo metabolism of CHF 6001, a selective phosphodiesterase (PDE4) inhibitor.
Cenacchi V, Battaglia R, Cinato F, et al. · Xenobiotica 2015
- PDE inhibitors currently in early clinical trials for the treatment of asthma.
Matera MG, Page C, Cazzola M · Expert Opin Investig Drugs 2014
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.